Preliminary application of 125I–nivolumab to detect PD-1 expression in colon cancer via SPECT

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

(2018) Dan Li et al.   MOLECULAR PHARMACEUTICS

89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer

(2017) Christopher G. England et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

(2017) Katrijn Broos et al.   Oncotarget

PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET

(2016) Wojciech G. Lesniak et al.   BIOCONJUGATE CHEMISTRY

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

(2016) Ryan Gentzler et al.   Immunotherapy

Molecular Imaging of Immunotherapy Targets in Cancer

(2016) E. B. Ehlerding et al.   JOURNAL OF NUCLEAR MEDICINE

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

(2015) S. Postel-Vinay et al.   ANNALS OF ONCOLOGY

Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

(2015) Arutselvan Natarajan et al.   BIOCONJUGATE CHEMISTRY

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer

(2015) Anders Josefsson et al.   CANCER RESEARCH

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PD-1 pathway: a promising future for the treatment of melanoma

(2014) Andrew Mamalis et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

(2014) Michael S. Gordon et al.   CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Cancer Immunotherapy Comes of Age

(2011) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

(2010) Carol M Lee et al.   BMC CANCER

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Imaging in the era of molecular oncology

(2008) Ralph Weissleder et al.   NATURE